132 related articles for article (PubMed ID: 38423635)
21. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E
BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
23. [Palliative chemotherapy of head and neck cancer: present status and future development].
Hennemann B
Laryngorhinootologie; 2006 Mar; 85(3):172-8. PubMed ID: 16547892
[TBL] [Abstract][Full Text] [Related]
24. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
25. Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis.
Tang L; Liu T; Chen J; Dang J; Li G
Immunotherapy; 2021 Apr; 13(6):541-555. PubMed ID: 33629592
[No Abstract] [Full Text] [Related]
26. Promising new molecular targeted therapies in head and neck cancer.
Dorsey K; Agulnik M
Drugs; 2013 Mar; 73(4):315-25. PubMed ID: 23440867
[TBL] [Abstract][Full Text] [Related]
27. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors.
Lai CL; Chen TH; Chang PM; Tai SK; Chu PY; Yang MH
J Chin Med Assoc; 2022 Jun; 85(6):687-692. PubMed ID: 35507025
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
van den Broek GB; Rasch CR; Pameijer FA; Peter E; van den Brekel MW; Tan IB; Schornagel JH; de Bois JA; Zijp LJ; Balm AJ
Cancer; 2004 Oct; 101(8):1809-17. PubMed ID: 15386309
[TBL] [Abstract][Full Text] [Related]
31. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
Swiecicki PL; Zhao L; Belile E; Sacco AG; Chepeha DB; Dobrosotskaya I; Spector M; Shuman A; Malloy K; Moyer J; McKean E; McLean S; Wolf GT; Eisbruch A; Prince M; Bradford C; Carey T; Worden FP
Invest New Drugs; 2015 Dec; 33(6):1248-56. PubMed ID: 26453566
[TBL] [Abstract][Full Text] [Related]
32. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study of a regional cancer center of North India (Asia).
Harsh KK; Maharia SR; Nirban RK; Khatri P; Beniwal S; Kumar HS; Jakhar SL
J Cancer Res Ther; 2020; 16(3):559-564. PubMed ID: 32719267
[TBL] [Abstract][Full Text] [Related]
33. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
34. Promising newer molecular-targeted therapies in head and neck cancer.
Wang LX; Agulnik M
Drugs; 2008; 68(12):1609-19. PubMed ID: 18681486
[TBL] [Abstract][Full Text] [Related]
35. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma.
Pestana RC; Becnel M; Rubin ML; Torman DK; Crespo J; Phan J; Hanna E; Bell D; Glisson BS; Johnson JM; Lee JJ; Ferrarotto R
Oral Oncol; 2020 Feb; 101():104523. PubMed ID: 31864957
[TBL] [Abstract][Full Text] [Related]
36. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
37. Endothelial growth factor receptor inhibitors in recurrent metastatic cancer of the head and neck.
Misiukiewicz K; Dang RP; Parides M; Camille N; Uczkowski H; Sarlis NJ; Posner M
Head Neck; 2016 Apr; 38 Suppl 1():E2221-8. PubMed ID: 25900280
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapies in head and neck cancer: past, present and future.
Rapidis AD; Vermorken JB; Bourhis J
Rev Recent Clin Trials; 2008 Sep; 3(3):156-66. PubMed ID: 18782074
[TBL] [Abstract][Full Text] [Related]
39. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.
Rühle A; Sprave T; Kalckreuth T; Stoian R; Haehl E; Zamboglou C; Laszig R; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Apr; 15(1):81. PubMed ID: 32299456
[TBL] [Abstract][Full Text] [Related]
40. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
